For skin cancers in this context, which class of DMARDs is preferred over others?

• A. csDMARDs
• B. bDMARDs
• C. JAK inhibitors
• D. No DMARDs

Answer: (A)

When skin cancer risk is a key concern, conventional synthetic DMARDs are favored because they provide useful disease control with less intense immunosuppression than biologic agents or JAK inhibitors. This means you can manage the inflammatory process while reducing the potential for inducing or worsening skin cancers. Biologic DMARDs (like TNF inhibitors) and JAK inhibitors carry a higher level of immune suppression, which can increase cancer risk or hinder cancer surveillance in some patients. In someone with a history of skin cancer or high risk, relying on conventional synthetic options such as methotrexate, hydroxychloroquine, or sulfasalazine is typically preferred, with careful monitoring for drug-specific safety concerns. If csDMARDs fail or are unsuitable, biologics or JAK inhibitors might be considered, but cancer risk considerations remain a key part of the decision.